Pediatric Nephrology

, Volume 24, Issue 2, pp 323–331 | Cite as

Diagnostic accuracy of urine dipsticks for detecting albuminuria in indigenous and non-indigenous children in a community setting

  • Leigh Haysom
  • Rita Williams
  • Elisabeth Hodson
  • Pamela Lopez-Vargas
  • L. Paul Roy
  • David Lyle
  • Jonathan C. Craig
Original Article


Albuminuria predicts cardiovascular and end-stage kidney disease in indigenous populations. Early detection in indigenous children may identify those who could benefit from early treatment. Community-based detection of albuminuria needs to be performed using a reliable, inexpensive, and widely available test, such as a proteinuria dipstick. Dipstick accuracy for detecting albuminuria in a community setting has not been evaluated. We assessed the accuracy of Multistix 10 SG dipsticks to detect baseline albuminuria and predict for persistent albuminuria at a 2-year follow-up in a population-based cohort of Australian Aboriginal and non-Aboriginal elementary-school-aged children. Variability in the accuracy of dipsticks in subgroups of higher risk children was analyzed using the relative diagnostic odds ratio (RDOR). Using Multistix 10 SG dipsticks, index-test-positive cases were defined as ≥0.30 g/L (1+) proteinuria and index-test-negative cases as <0.30 g/L (negative or trace) proteinuria. Referent-test-positive cases were defined as spot albumin:creatinine (ACR) ≥3.4 mg/mmol, and referent-test-negative cases as ACR <3.4 mg/mmol. There were 2,266 children (55.1% Aboriginal, 51.0% boys, mean age 8.9 years) enrolled. At the 2-year follow-up, 1,432 (63.0%) children were retested (54.0% Aboriginal, 50.5% boys, mean age 10.5 years). Prevalence of baseline albuminuria was 7.3%, and persistent albuminuria was 1.5%. Dipsticks had a sensitivity of 62% and specificity of 97% at baseline. In predicting persistent albuminuria, sensitivity was 75% and specificity 93%. Accuracy did not vary with ethnicity, gender, or body mass index. Accuracy was less in younger children (4.0–7.9 years), and in those with hematuria. The performance characteristics of Multistix dipsticks make them suitable for albuminuria detection in Aboriginal and other higher-risk groups of children. More than two thirds of children detected at a single test will have transient rather than persistent albuminuria. Multistix dipsticks are particularly useful for detecting children who will have persistent albuminuria.


Proteinuria Albuminuria Diagnostic test ACR Aboriginal Children 



We thank the Aboriginal communities, Aboriginal Medical Services, schools, Aboriginal Education Assistants, Aboriginal Area Health Workers, all families, and The Children’s Hospital nursing staff who participated in this study. We also thank Bayer for the loan of the Clinitek 50 urinalysis machine, The Far West Population Health Division, and Maari Ma Health Aboriginal Corporation for their assistance in visiting the remote communities. We acknowledge the financial support provided by the National Health and Medical Research Centre for Clinical Excellence in Renal Medicine, the Financial Markets Foundation for Children, and the National Health and Medical Research Council for the first author’s Training Scholarship in Indigenous Health Research.

Role of the funding source

Funding bodies had no role in the study design, data collection, data analysis, data interpretation, or writing of the report.

Conflict of interest statement

There were no competing interests identified in the data collection or writing of this manuscript.


  1. 1.
    Rhoades DA (2005) Racial misclassification and disparities in cardiovascular disease among American Indians and Alaska Natives. Circulation 111:1250–1256PubMedCrossRefGoogle Scholar
  2. 2.
    US Renal Data System (2006) Annual data report. Accessed 22 May 2008
  3. 3.
    Kidney Health Australia (2007) Fact sheet, 16 Feb 2007. Accessed 22 May 2008
  4. 4.
    ANZDATA 29th Annual Report. Accessed 22 May 2008
  5. 5.
    Cass A, Cunningham J, Wang Z, How W (2001) Regional variation in the incidence of end-stage renal disease in Indigenous Australians. Med J Aust 175:24–27PubMedGoogle Scholar
  6. 6.
    McDonald SP, Russ GR (2003) Current incidence, treatment patterns and outcome of end-stage renal disease among Indigenous groups in Australia and New Zealand. Nephrology 8:42–48PubMedCrossRefGoogle Scholar
  7. 7.
    White SL, Cass A, Atkins RC, Chadban SJ (2005) Chronic kidney disease in the general population. Adv Chronic Kidney Dis 12:5–13PubMedCrossRefGoogle Scholar
  8. 8.
    Hoy WE, Kondalsamy-Chennakesavan S, McDonald S, Wang Z (2006) Renal disease, the metabolic syndrome and cardiovascular disease. Ethn Dis 16(Suppl 2):46–51Google Scholar
  9. 9.
    Nelson RG, Meyer TW, Myers BD, Bennett PH (1997) Course of renal disease in Pima Indians with non-insulin dependent diabetes mellitus. Kidney Int 52(Suppl 63):S45–S48Google Scholar
  10. 10.
    Ebbesson SO, Adler AI, Risica PM, Ebbesson LO, Yeh JL, Go OT, Doolittle W, Ehlert G, Swenson M, Robbins DC (2005) Cardiovascular disease and risk factors in 3 Alaskan Eskimo populations: the Alaska-Siberia project. Int J Circumpolar Health 64:365–386PubMedGoogle Scholar
  11. 11.
    Baker PR, Hoy WE, Thomas RE (2005) Cost-effectiveness analysis of a kidney and cardiovascular disease treatment program in an Australian Aboriginal population. Adv Chronic Kidney Dis 12:22–31PubMedCrossRefGoogle Scholar
  12. 12.
    Shephard MD, Allen GG, Paizis K, Barbara JA, Batterham M, Vanajek A (2006) Results of an Aboriginal community-based renal disease management program incorporating point of care testing for urine albumin:creatinine ratio. Rural Remote Health 6:591PubMedGoogle Scholar
  13. 13.
    Gansevoort RT, Verhave JC, Hillege HL, Burgerhof JG, Bakker SJ, de Zeeuw D, de Jong PE, for the PREVEND Study Group (2005) The validity of screening based on spot morning urine samples to detect subjects with micro-albuminuria in the general population. Kidney Int Suppl 94:S28–S35PubMedCrossRefGoogle Scholar
  14. 14.
    Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326:41–44PubMedCrossRefGoogle Scholar
  15. 15.
    Australian Bureau of Statistics: Population Information – Distribution. Canberra (Australia). Commonwealth of AustraliaGoogle Scholar
  16. 16.
    National Health and Medical Research Council. Values and Ethics: Guidelines for ethical conduct in Aboriginal and Torres Strait Islander health research. Canberra (Australia). Commonwealth of AustraliaGoogle Scholar
  17. 17.
    National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification.
  18. 18.
    Vehaskari VM, Rapola J (1982) Isolated proteinuria: analysis of a school-age population. J Pediatr 101:661–668PubMedCrossRefGoogle Scholar
  19. 19.
    Shephard MDS: Analytical performance criteria for point-of-care testing instruments. In: Standards for point of care testing in general practice. Incorporating POCT guidelines. Canberra: Australian Government Department of Health and Ageing, pp 101–140Google Scholar
  20. 20.
    Ricos C, Alvarez V, Cava F, García-Lario JV, Hernández A, Jiménez CV, Minchinela J, Perich C, Simón M (1999) Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 59:491–500PubMedCrossRefGoogle Scholar
  21. 21.
    Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM (2003) The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 56:1129–1135PubMedCrossRefGoogle Scholar
  22. 22.
    Greenacre P (1997) Height and Weight Standard Deviation Score Calculator 1997. The Children’s Hospital at Westmead, New South Wales, Australia, p 2145Google Scholar
  23. 23.
    Haysom L, Williams R, Hodson E, Roy LP, Lyle D, Craig JC (2007) Early chronic kidney disease in Aboriginal and non-Aboriginal children: remoteness, socioeconomic disadvantage or race? Kidney Int 71:787–794PubMedCrossRefGoogle Scholar
  24. 24.
    Allen JK, Krauss EA, Deeter RG (1991) Dipstick analysis of urinary protein. A comparison of Chemstrip-9 and Multistix 10 SG. Arch Pathol Lab Med 115:34–37PubMedGoogle Scholar
  25. 25.
    Higby K, Suiter CR, Siler-Khodr T (1995) A comparison between two screening methods for detection of microproteinuria. Am J Obstet Gynaecol 173:1111–1114CrossRefGoogle Scholar
  26. 26.
    Wilson DM, Anderson RL (1993) Protein-osmolality ratio for the quantitative assessment of proteinuria from a random urinalysis sample. Am J Clin Pathol 100:419–424PubMedGoogle Scholar
  27. 27.
    Lijmer JG, Mol BW, Heisterkamp S, Bonsel GJ, Prins MH, van der Meulen JH, Bossuyt PM (1999) Empirical evidence of design related bias in studies of diagnostic tests. JAMA 282:1060–1066CrossRefGoogle Scholar
  28. 28.
    Irwig L, Bossuyt P, Glasziou P, Gatsonis C, Lijmer J (2002) Designing studies to ensure that estimates of test accuracy are transferable. BMJ 324:669–671PubMedCrossRefGoogle Scholar
  29. 29.
    Chitalia VC, Kothari J, Wells EJ, Livesey JH, Robson RA, Searle M, Lynn KL (2001) Cost-benefit analysis and prediction of 24 hour proteinuria from the spot urine protein-creatinine ratio. Clin Nephrol 55:436–447PubMedGoogle Scholar
  30. 30.
    Ruggenenti P, Gaspari F, Perna A, Remuzzi G (1998) Cross-sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end-stage renal failure in chronic renal disease in patients without diabetes. BMJ 316:504–509PubMedGoogle Scholar
  31. 31.
    Ginsberg JM, Chang BS, Matarese RA, Garella S (1983) Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 309:1543–1546PubMedGoogle Scholar
  32. 32.
    Bland JM, Altman DG (1995) Comparing two methods of clinical measurement: a personal history. Int J Epidemiol 24:S7–S14PubMedGoogle Scholar
  33. 33.
    Shemesh T, Rowley KG, Shephard M, Piers LS, O’Dea K (2006) Agreement between laboratory results and on-site pathology testing using Bayer DCA2000 + and Cholestech LDX point-of-care methods in remote Australian Aboriginal communities. Clin Chim Acta 367:69–76PubMedCrossRefGoogle Scholar
  34. 34.
    Cunningham J, Cass A, Arnold PC (2005) Bridging the treatment gap for Indigenous Australians. Demands for efficiency should not be met at the expense of equity. Med J Aust 182:505–506PubMedGoogle Scholar
  35. 35.
    Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Stamler J (1997) End-stage renal disease in African American and white men. 16 year MRFIT finding. JAMA 277:1293–1298PubMedCrossRefGoogle Scholar
  36. 36.
    Iseki K, Iseki C, Ikemiya Y, Fukiyama K (1996) Risk of developing end-stage renal disease in a cohort of mass screening. Kidney Int 49:800–805PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2008

Authors and Affiliations

  • Leigh Haysom
    • 1
    • 2
  • Rita Williams
    • 1
  • Elisabeth Hodson
    • 1
  • Pamela Lopez-Vargas
    • 1
  • L. Paul Roy
    • 3
  • David Lyle
    • 4
  • Jonathan C. Craig
    • 1
    • 2
  1. 1.Centre for Kidney ResearchThe Children’s Hospital at WestmeadWestmeadAustralia
  2. 2.School of Public HealthUniversity of SydneySydneyAustralia
  3. 3.PediatricsThe Children’s Hospital at WestmeadWestmeadAustralia
  4. 4.Department of Rural HealthUniversity of SydneySydneyAustralia

Personalised recommendations